Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2021 | Infectious complications after CAR T-cell therapy

Joshua Hill, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses infectious complications in patients receiving CAR T-cell therapy. In the first month after CAR T-cell therapy, most infections are bacterial, and the biggest risk factor appears to be severe cytokine release syndrome (CRS). At later time points, the incidence of infections decreases, and patients predominantly have respiratory virus infections. Furthermore, Dr Hill outlines infection prevention strategies such as vaccination and administration of IVIG supplementation. This interview took place during the 3rd European CAR T-cell Meeting.


Consultant for Gilead Sciences, Amplyx, Allovir, Allogene, Takeda, CRISPR
Research support from Takeda, Allovir, Karius, Gilead